Patents by Inventor Richard B. Silverman

Richard B. Silverman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10836708
    Abstract: Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical compositions containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 17, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Richard B. Silverman, Matthew Moschitto
  • Patent number: 10822301
    Abstract: Disclosed are cyclopentene compounds for use as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-carbon substituted 4-aminocyclopent-1-ene-carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, and hepatocellular carcinoma (HCC).
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 3, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Chi-Li Ni, Jose Juncosa
  • Publication number: 20200331910
    Abstract: Disclosed are compounds that are shown to inhibit the biological activity of nitric oxide synthases (NOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. Because the disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs), the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with NOS activity.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 22, 2020
    Inventors: Richard B. Silverman, Heng-Yen Wang, Yajuan Qin, Fengwei Zou, Soo Sung Kang, Qing Jing
  • Patent number: 10800753
    Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 13, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Hoang V. Le, Dustin D. Hawker
  • Publication number: 20200317606
    Abstract: Disclosed are enantiomerically pure cyclopentane-based compounds that are prepared by a multiple-step synthesis process. The disclosed compounds have been designed to inhibit gamma-aminobutyric acid-amino transferase (GABA-AT) activity and ornithine aminotransferase (OAT) activity. Some of the enantiomerically pure compounds inhibit OAT activity more potently than the racemic compound. The disclosed compounds may be used to selectively inhibit OAT activity, for example, to treat hepatocellular carcinoma and/or used to selected inhibit GABA-AT activity, for example, to treat neurological diseases and disorders.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 8, 2020
    Applicant: Northwestern University
    Inventor: Richard B. Silverman
  • Publication number: 20200299296
    Abstract: Disclosed are compound and methods of using the compounds for modulating ornithine aminotransferase (OAT) activity. The disclosed compound are characterized as analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid which may be formulated as therapeutic agents for treating diseases and disorders associated with ornithine aminotransferase (OAT) activity such as hepatocellular carcinoma and other cancers.
    Type: Application
    Filed: February 25, 2020
    Publication date: September 24, 2020
    Applicant: Northwestern University
    Inventors: Richard B. Silverman, Matthew J. Moschitto
  • Publication number: 20200283444
    Abstract: Disclosed are new small molecules having a substituted pyrimidine or substituted fused pyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including Gaucher's disease and neurological diseases and disorders such as genetic and sporadic synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy associated with aberrant glucocerebrosidase activity. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.
    Type: Application
    Filed: July 25, 2018
    Publication date: September 10, 2020
    Inventors: Dimitri KRAINC, Richard B. SILVERMAN
  • Publication number: 20200281880
    Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).
    Type: Application
    Filed: March 31, 2020
    Publication date: September 10, 2020
    Applicant: Northwestern University
    Inventors: Richard B. Silverman, Hoang V. Le, Rima L. McLeod, Dustin D. Hawker
  • Patent number: 10759791
    Abstract: Disclosed are compounds that are shown to inhibit the biological activity of nitric oxide synthases (NOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. Because the disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs), the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with NOS activity.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: September 1, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Heng-Yen Wang, Yajuan Qin, Fengwei Zou, Soo Sung Kang, Qing Jing
  • Patent number: 10751341
    Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: August 25, 2020
    Assignee: Lysosomal Therapeutics Inc.
    Inventors: Renato T. Skerlj, Peter T. Lansbury, Andrew C. Good, Elyse Marie Josee Bourque, Richard B. Silverman, Dimitri Krainc, Jianbin Zheng
  • Publication number: 20200179368
    Abstract: Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 11, 2020
    Applicants: Northwestern University, Chapman University
    Inventors: Richard B. Silverman, Sun Yang
  • Patent number: 10632088
    Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 28, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Hoang V. Le, Rima L. McLeod, Dustin D. Hawker
  • Publication number: 20200071292
    Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Applicant: Northwestern University
    Inventors: Dimitri Krainc, Richard B. Silverman, Jianbin Zheng
  • Publication number: 20200071334
    Abstract: Disclosed are new small molecules having a pyrrolopyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, includin neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may be utilized to generate activated glucocerebrosidase. The activated glucocerebrosidase thusly generated can be administered in enzyme replacement therapy and/or utilized in screening assays for new small molecules that bind to the activated glucocerebrosidase and/or modulate the activity of the activated glucocerebrosidase.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Applicant: Northwestern University
    Inventors: Dimitri Krainc, Richard B. Silverman, Jianbin Zheng
  • Publication number: 20200030331
    Abstract: The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof.
    Type: Application
    Filed: June 26, 2019
    Publication date: January 30, 2020
    Inventors: Renato T. Skerlj, Peter T. Lansbury, Andrew C. Good, Elyse Marie Josee Bourque, Richard B. Silverman, Dimitri Krainc, Jianbin Zheng
  • Publication number: 20200010474
    Abstract: Disclosed are new small molecules having a 4-methylpyrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Inventors: Dimitri Krainc, Richard B. Silverman, Jianbin Zheng
  • Patent number: 10526289
    Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 7, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Yinan Zhang
  • Patent number: 10501435
    Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: December 10, 2019
    Assignee: Northwestern University
    Inventors: Dimitri Krainc, Richard B. Silverman, Jianbin Zheng
  • Publication number: 20190359555
    Abstract: Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical compositions containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
    Type: Application
    Filed: May 28, 2019
    Publication date: November 28, 2019
    Inventors: Richard B. Silverman, Matthew MOSCHITTO
  • Publication number: 20190315677
    Abstract: Disclosed are cyclopentene compounds for use as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-carbon substituted 4-aminocyclopent-1-ene-carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, and hepatocellular carcinoma (HCC).
    Type: Application
    Filed: April 4, 2019
    Publication date: October 17, 2019
    Applicant: Northwestern University
    Inventors: Richard B. Silverman, Chi-Li Ni, Jose Juncosa